To access this element change to forms mode OFF
Grant Award View - GA279510
Exploring the anti-apoptotic and apoptosis-unrelated functions of MCL-1...
GA ID:
GA279510
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
27-Oct-2022
Publish Date:
23-Jan-2023
Category:
Medical Research
Grant Term:
1-Jan-2023 to 31-Dec-2025
Value (AUD):
$863,108.38
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 21/22 1.1 Health and Medical Research
Grant Program:
Ideas Grants
Grant Activity:
Exploring the anti-apoptotic and apoptosis-unrelated functions of MCL-1 during embryonic and blood cell development to advance MCL-1 inhibitors in clinical trials for cancer
Purpose:
In a healthy organism damaged or autoreactive cells kill themselves by a controlled cell death program, called apoptosis. Pro-survival proteins (e.g. MCL-1) block apoptosis, and their enhanced expression causes cancer. Some pro-survival inhibitory drugs (e.g. Venetoclax) are effective and well tolerated, whereas the highly effective MCL-1 inhibitors cause intolerable side effects in clinical trials. This project aims to determine the differences of these proteins to improve cancer therapy.
GO ID:
GO Title:
Ideas Grants 2022
Internal Reference ID:
2022/GNT2021510
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
The Walter and Eliza Hall Institute of Medical Research
Recipient ABN:
12 004 251 423
Grant Recipient Location
Suburb:
Parkville
Town/City:
Parkville
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
ACT, VIC
Postcode:
Multiple
Country:
AUSTRALIA